Capreomycin sulfate microbiology: Difference between revisions
No edit summary |
Gerald Chi (talk | contribs) mNo edit summary |
||
| (One intermediate revision by the same user not shown) | |||
| Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Capreomycin sulfate}} | {{Capreomycin sulfate}} | ||
{{CMG}} ; {{AE}}{{chetan}} | {{CMG}}; {{AE}} {{chetan}} | ||
==Microbiology== | ==Microbiology== | ||
Capreomycin is active against strains of Mycobacterium tuberculosis found in humans. | Capreomycin is active against strains of ''[[Mycobacterium tuberculosis]]'' found in humans. | ||
===Susceptibility Tests=== | ===Susceptibility Tests=== | ||
| Line 12: | Line 12: | ||
===Cross-Resistance=== | ===Cross-Resistance=== | ||
Frequent cross-resistance occurs between capreomycin and viomycin. Varying degrees of cross-resistance between capreomycin and kanamycin and neomycin have been reported. No cross-resistance has been observed between capreomycin and isoniazid, aminosalicylic acid, cycloserine, streptomycin, ethionamide, or ethambutol.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CAPASTAT SULFATE (CAPREOMYCIN) INJECTION, POWDER, FOR SOLUTION [AKORN] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=808e4421-2b9c-41e1-a82c-39256b112ae8 | publisher = | date = | accessdate }}</ref> | Frequent cross-resistance occurs between capreomycin and viomycin. Varying degrees of cross-resistance between capreomycin and kanamycin and neomycin have been reported. No cross-resistance has been observed between capreomycin and isoniazid, aminosalicylic acid, cycloserine, streptomycin, ethionamide, or ethambutol.<ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = CAPASTAT SULFATE (CAPREOMYCIN) INJECTION, POWDER, FOR SOLUTION [AKORN] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=808e4421-2b9c-41e1-a82c-39256b112ae8 | publisher = | date = | accessdate }}</ref> | ||
Latest revision as of 23:45, 25 December 2013
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]
Microbiology
Capreomycin is active against strains of Mycobacterium tuberculosis found in humans.
Susceptibility Tests
The in vitro susceptibility of strains of M. tuberculosis to capreomycin varies with the media and techniques employed. In general, the minimum inhibitory concentrations for M. tuberculosis are lowest in liquid media that are free of egg protein (7H10 or Dubos) and range from 1 to 5 μg/mL when the indirect method is used. Comparable inhibitory concentrations are obtained when 7H10 agar is used for direct susceptibility testing. When indirect susceptibility tests are performed on standard tube slants with 7H10 media, susceptible strains are inhibited by 10 to 25 μg/mL capreomycin. Egg-containing media, such as Löwenstein-Jensen or ATS, require concentrations of 25 to 50 μg/mL to inhibit susceptible strains.
Cross-Resistance
Frequent cross-resistance occurs between capreomycin and viomycin. Varying degrees of cross-resistance between capreomycin and kanamycin and neomycin have been reported. No cross-resistance has been observed between capreomycin and isoniazid, aminosalicylic acid, cycloserine, streptomycin, ethionamide, or ethambutol.[1]
References
- ↑ "CAPASTAT SULFATE (CAPREOMYCIN) INJECTION, POWDER, FOR SOLUTION [AKORN]". Text " accessdate " ignored (help)
Adapted from the FDA Package Insert.